Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Sponsor: Crozer-Keystone Health System
Listed as NCT04467983, this PHASE4 trial focuses on Osteoporosis, Postmenopausal and remains ongoing. Sponsored by Crozer-Keystone Health System, it has been updated 9 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE4
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Oct 2024 — Jun 2025 [monthly]
Recruiting PHASE4
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
▶ Show 4 earlier versions
-
Mar 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Mar 2021 — Mar 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE4
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Crozer-Keystone Health System
- Hospital for Special Surgery, New York
- Radius Health, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .